In the United States of America, adjuvant tamoxifen therapy is now approved for the treatment of postmenopausal node positive patients after the surgical excision of early breast cancer. The National Institute of Health has recommended this treatment for those patients who, in addition, have oestrogen receptor positive primary tumours (Consensus Conference, 1985) .
The previous analyses of the Nolvadex Adjuvant Trial Organisation (NATO) study (Nolvadex AdjuVant Trial Organisation, 1983a , 1983b had an important influence on this recommendation. It is therefore of particular interest to review the more mature data from this trial. This analysis presents the results at a median follow up of 66 months and in particular, examines the duration of treatment effect and the relationship between prognostic variables and the treatment effect.
Trial design and statistical methods
Full details are described in previous papers (Nolvadex Adjuvant Trial Organisation, 1983a Organisation, , 1983b Organisation, , 1985 . From November 1977 to February 1981, 1,285 patients aged 75 years or less were randomised to receive either 10mg tamoxifen (Nolvadex) twice daily for two years or no further treatment following total mastectomy with axillary node clearance or sampling. Node positive patients as determined by node sampling received regional radiotherapy. Of the 642 patients randomised to tamoxifen and the 643 patients receiving no further treatment, 76 and 75 patients respectively were withdrawn from the analysis because they did not satisfy the selection criteria, and two and one patients respectively have no entry or follow up data.
This analysis is based on 564 tamoxifen treated and 567 control patients who satisfy the eligibility criteria and have been followed for a median of five and a half years (range 8-94 months). A total of 525 primary tumour specimens were assayed for ER content by modifications of the dextran coated charcoal method in laboratories in Glasgow, Manchester, Cardiff (Tenovus Institute), London (ICRF) and Auckland, New Zealand. Quality control between laboratories was not part of this study but good agreement between the British laboratories was subsequently shown in the UK quality control study (Cowan & Leake 1984; King et al., 1978 (Cox, 1972) There was no evidence that tamoxifen increased the number of deaths due to causes other than cancer (Table III) (34 tamoxifen vs. 43 control).
kI--I The Macmillan Press Ltd., 1988 ,Br. J. Cancer (1988 The results of the log hazard ratio analysis for events and deaths are shown in Figures 3 and 4 . In the first two year time segment (i.e., the adjuvant treatment period) the log hazard ratio for events (Figure 3) is -0.6 with 95% confidence limits between -0.3 and -0.85. There is therefore a beneficial treatment effect which is statistically significant. Moving to the 24-48 months and 48-72 months time segments, the treatment effects are smaller and no longer statistically significant. In the fourth period the log ratio of hazard rates is greater than zero, but patient numbers are small and the confidence limits which span zero are wide. A similar pattern may be seen for the survival data (Figure 4) . A statistically significant treatment benefit is seen between months 24 and 48. This is reduced and is not statistically significant between months 48 and 72. The log hazard rate ratio is greater than 0 between 72 and 96 months, again this does not represent a rebound phenomenon with an accelerated death rate in the treated group due to the small numbers of patients at risk and the width of the confidence limits which span zero. Figure 3 Log ratio of hazard rates (with 95% confidence limits). The population was divided according to menopausal and nodal status and observed to expected ratios calculated for tamoxifen and no treatment groups (Table IV) . The multivariate regression analysis did not detect any significant variation in treatment effect between subgroups. The observed to expected ratios favour tamoxifen treatment equally in each subgroup.
The ER status of the primary tumour was a significant prognostic variable. At cut-off values of 5 and 30fmolmg-1 cytosol protein, ER positive patients had a significantly better prognosis for both events and deaths (Table V) .
The population was divided according to ER status and observed to expected ratios calculated for each treatment group (stratified for the effects of menopausal and nodal status). Observed to expected ratios favoured the tamoxifen treated patients in each subgroup. The multivariate regression analysis again did not detect any significant variation in treatment effect between ER subgroups (Table VI) .
The histological grade of the primary tumour is a prognostic variable (Table VII) and is associated with the ER status at cut off values of 5fmol and 30fmol (Table VIII) . The greatest benefit for treatment is in grade I and II tumours compared to grade III tumours (Table IX) .
Discussion
At a maximum follow up of 8 years adjuvant tamoxifen therapy prescribed for two years after surgery continues to be associated with a significant reduction in the number of events and deaths. This benefit is independent of menopausal, nodal and ER status. There is no evidence of a rebound increase in number of events or deaths on withdrawal of treatment. However, the hazard ratio is greater than zero after 6 years. This is not significant and a final conclusion about this important consideration must await further follow up.
With regard to the hazard ratios, adjuvant tamoxifen seems to have an immediate effect on events but a delayed effect on survival. This difference in effect suggests either that prolonged treatment is necessary to improve mortality or that the greatest effect of treatment occurs in patients with a life expectancy of two to four years after the operation. The latter interpretation seems unlikely in view of the lack of interaction between the treatment effect and prognostic variables. If the former is true then prolongation of treatment might provide additional improvements in survival. This concept is supported by studies of MCF-7 cells Regression analysis showed no significant interaction between subgroups and tamoxifen effect. (Lykkesfeldt et al., 1984) . In advanced breast cancer ER, histological grade and disease free interval are dependent variables which predict responsiveness to endocrine therapy. In this trial none of these variables predicted the response to adjuvant therapy. There are two criticisms which must be countered before discussing some possible reasons for these differences in the response of advanced and early disease. Firstly, inadequate quality control in the assay of ER: this is unlikely because this trial concurred with many other studies showing that ER is a prognostic variable and is associated with histological grade. Secondly, lack of statistical power: clearly the power to detect a significant treatment effect within subgroups is much less than for the study as a whole, however the observed to expected ratios are remarkably consistent (with the possible exception of tumours of grade III malignancy) and in favour of tamoxifen treatment in each subgroup investigated. To summarize then, although ER status and histological grade were found to be prognostic indicators for the groups as a whole, therefore acting as an internal check on validity of the methods, no subgroup based on these variables was associated with a qualitative advantage for adjuvant tamoxifen treatment.
The absence of a correlation between ER status and treatment effects suggests that tamoxifen may have antitumour actions independent of the oestrogen receptor. The studies of Sutherland et al. (1986) on human breast cancer cells in tissue culture have clearly demonstrated two distinct mechanisms of growth inhibition. In addition to ERmediated, oestrogen-reversible growth inhibition, high concentrations of tamoxifen produce oestrogen-irreversible growth inhibition. The latter effect is distinguished from a non-specific cytoxic mechanism by its cell cycle specificity (Sutherland et al., 1983) . Both growth inhibitory mechanisms are confined to a precise time in the G1 phase of the cell cycle and may converge on common pathways which control cell division. Several candidate mechanisms for such effects have emerged recently which may be the target for tamoxifen action. These include inhibition of protein kinase C (O'Brien et al., 1986) and calmodulin action (Lam, 1984) . Calmodulin plays an important role in the control of cell cycle progression and may also be involved in ER activation.
It is clear from immunocytochemical studies using a monoclonal antibody to detect ER in human breast tumours that expression of ER is highly heterogeneous (Marchetti et al., 1985) . In addition Knabbe et al. (1987) Finally, are we in a position to make therapeutic recommendations? This trial is not the only one to show a significant benefit from adjuvant tamoxifen and the result can be judged 'typical' in the light of a world overview of tamoxifen trials (Peto, personal comm; Anonymous, 1984) . The drug itself is virtually free from significant side effects up to 8 years of follow up and the life table plot describes benefit for the group in terms of a relative risk reduction of about 30%. As there is no apparent interaction between treatment and prognostic subgroups, the greater the risk of relapse, the greater the absolute risk reduction following treatment with tamoxifen (e.g. 30% risk of relapse over 5 years, absolute risk reduction with tamoxifen=9%; 10% risk of relapse over 5 years, absolute risk reduction with tamoxifen=3%). Clinicians can now make rational decisions about whether or not to prescribe tamoxifen which are likely to differ from the NIH consensus recommendation which only recommended the drug for postmenopausal women with ER + tumours.
Our final plea is to clinicians who still have an open mind on the subject to enter patients into trials comparing 2 years with 5 years of adjuvant therapy or trials investigating the role of radiotherapy amongst patients receiving adjuvant tamoxifen therapy as a standard.
